Publication: An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC
Submitted Date
Received Date
Accepted Date
Issued Date
2020-01-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
15561380
15560864
15560864
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-85086020844
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Journal of Thoracic Oncology. (2020)
Citation
Viola W. Zhu, Yen Ting Lin, Dong Wan Kim, Herbert H. Loong, Misako Nagasaka, Hao To, Yvonne Li En Ang, Chan Young Ock, Nishan Tchekmedyian, Sai Hong Ignatius Ou, Nicholas L. Syn, Thanyanan Reungwetwattana, Chia Chi Lin, Ross A. Soo (2020). An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/58338.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
National Taiwan University Hospital
Yong Loo Lin School of Medicine
National Taiwan University College of Medicine
Seoul National University Hospital
Wayne State University School of Medicine
National University of Singapore
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
UCI School of Medicine
University of Nevada School of Medicine
Chinese University of Hong Kong
Pacific Shores Medical Group
Yong Loo Lin School of Medicine
National Taiwan University College of Medicine
Seoul National University Hospital
Wayne State University School of Medicine
National University of Singapore
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
UCI School of Medicine
University of Nevada School of Medicine
Chinese University of Hong Kong
Pacific Shores Medical Group
Series
Has Part
Abstract
© 2020 International Association for the Study of Lung Cancer Introduction: Lorlatinib, a next-generation central nervous system–penetrant ALK/ROS1 tyrosine kinase inhibitor (TKI), is approved to treat TKI-refractory ALK-positive (ALK+) NSCLC based on results from a phase 2 study. Methods: A real-world analysis was performed on ALK+ or ROS1-positive (ROS1+) patients with NSCLC enrolled in lorlatinib early or expanded access programs in Hong Kong, Singapore, South Korea, Taiwan, Thailand, and the United States. Results: A total of 95 patients with NSCLC (76 ALK+ and 19 ROS1+) were analyzed. Among ALK+ patients treated with less than two previous TKIs, two or more previous TKIs, and three or more previous TKIs, the objective response rates (ORR) and median progression-free survival (mPFS) were 42% (95% confidence interval [CI]: 26–59; n = 38) and not reached (NR) (95% CI: 4.5–NR; n = 45), 35% (95% CI: 22–49; n = 55) and 11.2 months (95% CI: 4.5–NR; n = 66), and 18% (95% CI: 4–43; n = 17) and 6.5 months (95% CI: 3.5–11.6; n = 21), respectively. The ORRs and mPFSs were 13% (95% CI: 0–53; n = 8) and 9.2 months (95% CI: 3.3–NR; n = 9) for patients treated with one second-generation ALK TKI as the only ALK TKI received. For ROS1+ patients, ORRs and mPFSs were 41% (95% CI: 18–67; n = 17) and 11.9 months (95% CI: 6.4–NR; n = 19). The intracranial ORRs were 35% (95% CI: 22–49) and 55% (95% CI: 23–83) for 52 ALK+ and 11 ROS1+ patients. mPFS was 9.3 months (95% CI: 1.0–NR; n = 13) for patients with leptomeningeal carcinomatosis. No new safety signals were noted. Conclusion: Lorlatinib exhibited meaningful activity in TKI-refractory ALK+ or ROS1+ patients with NSCLC enrolled in early or expanded access programs.